Lv1
43 积分 2023-10-24 加入
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
11小时前
待确认
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
14小时前
已完结
Managing toxicities of high-dose interleukin-2
8天前
已关闭
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
8天前
已完结
Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial
1个月前
已完结
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
1个月前
已完结
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
1个月前
已完结
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
1个月前
已完结
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
1个月前
已完结
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
1个月前
已完结
皖公网安备34019202002308
